Core Viewpoint - Sana Biotechnology, Inc. will present a business overview and update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 9:45 a.m. PT [1] Company Overview - Sana Biotechnology focuses on creating and delivering engineered cells as medicines, aiming to repair and control genes, replace missing or damaged cells, and make therapies widely available [3] - The company operates in Seattle, WA, Cambridge, MA, and South San Francisco, CA [3] Presentation Details - The presentation will be accessible via a webcast on the Investor Relations page of Sana's website, with a replay available for 30 days post-conference [2]

Core Viewpoint - Analysts are optimistic about Sana Biotechnology Inc. (NASDAQ: SANA), with multiple Buy ratings and a focus on its strategic initiatives and financial stability, suggesting it is a strong investment opportunity. Group 1: Analyst Ratings and Price Targets - Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating on Sana Biotechnology and set a price target of $6.00 [1] - TD Cowen analyst Marc Frahm also maintained a Buy rating, highlighting the company's strategic focus on the SC451 program while pausing allogeneic CAR T development to conserve cash [2] - Citizens initiated coverage of Sana Biotechnology with a Market Perform rating, indicating a positive outlook for the company [4] Group 2: Financial Position and Strategic Focus - Sana Biotechnology has a cash position of $170 million, which supports its strategic focus and financial stability [3] - The company is advancing its SG293 program, with an Investigational New Drug (IND) filing possible by 2027, and has gained FDA clarity on key steps toward an IND filing for SC451 in 2026 [3] - As of August, the company had $143 million in cash, positioning it well to enhance its diabetes program [5] Group 3: Market Potential and Growth Projections - Eric Jackson from EMJ Capital believes Sana Biotechnology could become a $100 billion company, driven by its diabetes therapy targeting 10% of the global Type 1 diabetes population at $100,000 per patient [5] - The company develops engineered cells as medicines to treat various diseases, focusing on gene repair, damaged cell replacement, and conditions like cancer and diabetes [6]

Core Points - Sana Biotechnology, Inc. will present at the TD Cowen Immunology & Inflammation Summit on November 12, 2025, at 1:30 p.m. ET, featuring a business overview by CEO Steve Harr [1] - The presentation will be available via webcast on the company's Investor Relations page, with a replay accessible for 30 days post-conference [2] - Sana Biotechnology focuses on engineered cells as medicines, aiming to repair genes and replace damaged cells, with operations in Seattle, Cambridge, and South San Francisco [3]

Core Viewpoint - Sana Biotechnology, Inc. is set to present at four investor conferences in September 2025, providing a business overview and updates on its engineered cell therapies [1][5]. Company Overview - Sana Biotechnology focuses on creating engineered cells as medicines, aiming to repair and control genes, and replace missing or damaged cells [3]. - The company operates in Seattle, WA, Cambridge, MA, and South San Francisco, CA [3]. Upcoming Events - Sana will present at the following conferences: - Citi's 2025 Biopharma Back-to-School Conference on September 2, 2025, at 3:15 p.m. ET [5]. - 2025 Wells Fargo Healthcare Conference on September 4, 2025, at 8:00 a.m. ET [5]. - Morgan Stanley 23 Annual Global Healthcare Conference on September 8, 2025, at 11:30 a.m. ET [5]. - HC Wainwright 27 Annual Global Investment Conference on September 9, 2025, at 9:30 a.m. ET [5]. Investor Relations - Webcasts of the presentations will be available on the Investor Relations page of Sana's website, with replays accessible for 30 days post-conference [2].

Group 1 - Sana Biotechnology, Inc. has successfully closed the sale of 3,358,208 shares of its common stock at a price of $3.35 per share, resulting in total gross proceeds of approximately $86.3 million [1] - The offering was part of a previously announced underwritten public offering that closed on August 8, 2025, and included the full exercise of the underwriters' option to purchase additional shares [1] - The joint book-running managers for the offering included Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen [2] Group 2 - The offering was conducted under a Registration Statement on Form S-3, which was previously filed and declared effective by the SEC [3] - Final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are accessible through the SEC's website [3] - Sana Biotechnology is focused on creating and delivering engineered cells as medicines for patients, with operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA [5]